Roche, Zealand Co-Development Petrelintide
This is a news story, published by Yahoo Finance, that relates primarily to Pharma news.
Pharma news
For more Pharma news, you can click here:
more Pharma newsdrug discoveries news
For more drug discoveries news, you can click here:
more drug discoveries newsYahoo Finance news
For more news from Yahoo Finance, you can click here:
more news from Yahoo FinanceAbout the Otherweb
Otherweb, Inc is a public benefit corporation, dedicated to improving the quality of news people consume. We are non-partisan, junk-free, and ad-free. We use artificial intelligence (AI) to remove junk from your news feed, and allow you to select the best health news, business news, entertainment news, and much more. If you like drug discoveries news, you might also like this article about
Danish obesity drug maker Zealand Pharma. We are dedicated to bringing you the highest-quality news, junk-free and ad-free, about your favorite topics. Please come every day to read the latest obesity therapy drug news, petrelintide news, drug discoveries news, and other high-quality news about any topic that interests you. We are working hard to create the best news aggregator on the web, and to put you in control of your news feed - whether you choose to read the latest news through our website, our news app, or our daily newsletter - all free!
Zealand PharmaReuters
•Health
Health
Roche pairs with Zealand Pharma on obesity drug candidate

81% Informative
Danish drug maker Zealand Pharma to co-develop petrelintide as an obesity therapy drug.
Zealand Pharma will receive upfront cash payments of $1.65 billion , with the possibility of milestone payments of up to $5.3 billion based on a phase 3 trial and sales development.
VR Score
90
Informative language
95
Neutral language
82
Article tone
formal
Language
English
Language complexity
61
Offensive language
not offensive
Hate speech
not hateful
Attention-grabbing headline
not detected
Known propaganda techniques
not detected
Time-value
medium-lived
External references
no external sources
Source diversity
no sources
Affiliate links
no affiliate links